Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiac reserve

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    90 result(s) found for: Cardiac reserve. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2006-004785-14 Sponsor Protocol Number: CNF1340-SCLC-002 Start Date*: 2007-04-03
    Sponsor Name:Celgene Corporation
    Full Title: A Phase II Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First-Line Platinum-based Chem...
    Medical condition: Extensive Disease Small Cell Lung Cancer that is refractory or progressive
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041068 Small cell lung cancer extensive stage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002788-80 Sponsor Protocol Number: Uni-Koeln-4243 Start Date*: 2020-09-09
    Sponsor Name:University of Cologne
    Full Title: An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH) (MPO-PAH)
    Medical condition: Group 1: Pulmonary arterial hypertension (PAH) Group 2: Postcapillary pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002226-13 Sponsor Protocol Number: 2014011723 Start Date*: 2014-11-26
    Sponsor Name:Rigshospitalet
    Full Title: A multimodality imaging approach for early detection and prediction of cardiotoxicity in Doxorubicin-treated patients with malignant lymphom
    Medical condition: Hodgkin and non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    17.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    17.1 10005329 - Blood and lymphatic system disorders 10025322 Lymphomas non-Hodgkin's unspecified histology HLGT
    17.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001523-69 Sponsor Protocol Number: V-CHANCE Start Date*: 2014-07-28
    Sponsor Name: Istituto Nazionale Tumori di Napoli - Fondazione "G. Pascale"
    Full Title: Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck
    Medical condition: Recurrent and/or metastatic squamous cell carcinoma of head and neck
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018363-42 Sponsor Protocol Number: DOXERT1 Start Date*: 2010-09-15
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A phase II dose finding study of induction cisplatin, docetaxel and escalating doses of capecitabine followed by concurrent cetuximab and radiotherapy in locally advanced inoperable head and neck s...
    Medical condition: locally advanced inoperable head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026660 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001945-42 Sponsor Protocol Number: CRLX030A2203 Start Date*: 2013-09-26
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the effects of intravenous serelaxin infusion on micro- and macrovascular function in patients with cor...
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001018-14 Sponsor Protocol Number: UCART123_03 Start Date*: 2018-11-15
    Sponsor Name:CELLECTIS SA
    Full Title: Phase I, open label dose-escalation study to evaluate the safety, expansion, persistence and clinical activity of multiple infusions of UCART123 (allogeneic engineered T-cells expressing anti-CD123...
    Medical condition: Adverse genetic Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000878 Acute myeloblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000065-38 Sponsor Protocol Number: ASL607LIOM01 COMET-GI Start Date*: 2007-02-28
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: METRONOMIC CHEMOTHERAPY WITH URACIL/TEGAFUR (UFT), CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB IN PRETREATED PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES: A PILOT CLINICAL STUDY WITH PHARMACOKINET...
    Medical condition: PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061174 Gastrointestinal neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005637-47 Sponsor Protocol Number: ESR-14-10637 Start Date*: 2017-04-27
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Randomized study of AZD9291 treatment of EGFR M+ NSCLC patients progressing on first line erlotinib. A study based upon detection of EGFR M+ ctDNA in plasma and urine.
    Medical condition: Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003098-21 Sponsor Protocol Number: VINORAD OVER 70 Start Date*: 2007-08-02
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: INTEGRATED PROTOCOL OF CHEMO-RADIOTHERAPY IN THE TREATMENT OF THE OLD PATIENTS WITH NSCLC STAGE III. PHASE II TRIAL
    Medical condition: Enrolment of old patient with age over 70, with Non Small Cell Lung Cancer, not operable stage IIIA and IIIB
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029519 Non-small cell lung cancer stage III LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003075-39 Sponsor Protocol Number: TXTGEM OVER 70 Start Date*: 2007-07-12
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: PROTOCOL OF TREATMENT WITH DOCETAXEL-GEMCITABINE IN OLD OR UNFIT PATIENTS WITH NSCLC STAGE IIIA, IIIB E IV. PHASE II TRIAL
    Medical condition: Enrolment of old or unfit patient with age over 70, with Non Small Cell Lung Cancer, not operable stage IIIA, IIIB, IV
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000281-21 Sponsor Protocol Number: H6Q-MC-S039 Start Date*: 2007-09-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter G...
    Medical condition: primary glioma without methylation of the promoter gene of MGMT enzyme
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001404-38 Sponsor Protocol Number: FIL_GEMRO Start Date*: 2012-07-12
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Medical condition: Relapsed/refractory peripheral T-cell lymphoma patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000696-25 Sponsor Protocol Number: FOLRT Start Date*: 2016-06-07
    Sponsor Name:UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA
    Full Title: INDUCTION FOLFIRINOX AND RADIOCHEMOTHERAPY IN LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
    Medical condition: LOCALLY ADVANCED PANCREATIC CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001141 Adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004530-38 Sponsor Protocol Number: ASSTBS-FARONCO-PESETA-20 Start Date*: 2022-05-30
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENALCORTICAL (PESETA TRIAL)
    Medical condition: advanced/ metastatic patients with ACC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001388 Adrenocortical carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005722-28 Sponsor Protocol Number: 2020/3188 Start Date*: 2021-04-29
    Sponsor Name:Gustave Roussy
    Full Title: Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response t...
    Medical condition: Patients with human epidermal growth factor receptor 3-overexpressing (HER3-high) and hormone-receptor positive (HR+) advanced breast cancer who have already received standard therapy for HR+ advan...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002615-25 Sponsor Protocol Number: GE-262-001 Start Date*: 2020-03-27
    Sponsor Name:GE Healthcare Ltd.
    Full Title: An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Paediatric Patients
    Medical condition: Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacolo...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10028603 Myocardial perfusion scan LLT
    20.0 100000004848 10065141 Vascular diagnostic procedure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004630-41 Sponsor Protocol Number: H6Q-MC-JCBJ Start Date*: 2006-04-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
    Medical condition: high-risk diffuse large B-cell lymphoma (DLBCL )
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) ES (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) IT (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000037-14 Sponsor Protocol Number: NEOD001-301 Start Date*: 2021-09-01
    Sponsor Name:Prothena Biosciences Limited
    Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with ...
    Medical condition: AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004455-32 Sponsor Protocol Number: IMB101-006 Start Date*: 2021-02-16
    Sponsor Name:Imbria Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Patients with Angina due to Coronary Syndrome
    Medical condition: Stable coronary artery disease (CAD) /Chronic coronary syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 04:39:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA